Blood biomarker changes in response to low-dose oral ketamine treatment in adults with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD)
medRxiv August 14, 2026 Annette M Braxton, Christina Driver, Daniel F. Hermens et al. preprint
Abstract Major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) are prevalent, chronic, and disabling mental health conditions which are difficult to treat. Ketamine has demonstrated effect for improving depression and PTSD symptoms independently but reports often overlook focused comorbid improvement of these symptoms within individuals. To address this, we assessed...